Market Cap 110.93M
Revenue (ttm) 570,000.00
Net Income (ttm) -26.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,636.84%
Debt to Equity Ratio 0.00
Volume 1,429,700
Avg Vol 3,208,340
Day's Range N/A - N/A
Shares Out 71.11M
Stochastic %K 52%
Beta 0.35
Analysts Strong Sell
Price Target $4.50

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 661 7661
Fax: 646 661 4027
Address:
441 Ninth Avenue, 14th Floor, New York, United States
swingtraderqueen
swingtraderqueen Oct. 23 at 2:15 PM
$OVID all in on this $YYAI $ZOMDF $BYND
0 · Reply
swingtraderqueen
swingtraderqueen Oct. 23 at 2:14 PM
0 · Reply
venkbaskar
venkbaskar Oct. 21 at 7:26 PM
$OVID $5 in January
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 21 at 3:25 PM
$OVID Added some
0 · Reply
lucabrix
lucabrix Oct. 20 at 7:35 PM
$OVID great times in front of us!
0 · Reply
Tonydarien
Tonydarien Oct. 20 at 2:56 PM
$OVID same old crap, a different smell. Day traders playing this in a $0.35 channel. We need positive top line for OV350 to launch this to $3.00.
0 · Reply
therealcryptocowboy
therealcryptocowboy Oct. 19 at 12:22 AM
$OVID need help fam please sign and share! https://c.org/XbNrDf8F6r
0 · Reply
stocksmanagement
stocksmanagement Oct. 18 at 6:22 AM
$OVID Check out this article from TipRanks | Ovid Therapeutics price target raised to $5 from $3 at B. Riley | https://tipranks.onelink.me/WJho/9vnu72lg
0 · Reply
docBNM
docBNM Oct. 17 at 5:01 PM
$OVID seems like the supposed good news is not impressing Mr. Mkt. How low will this POS go ??!?!?!
0 · Reply
Troopers
Troopers Oct. 17 at 1:12 PM
$OVID OV329 was studied in models of neuropathic pain and inflammatory pain, and it showed great activity against pain in both models. Importantly, it didn’t show tolerance or addiction. The study was published in PNAS (link below). These would be blockbuster indications! “Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction” https://www.pnas.org/doi/10.1073/pnas.2318833121
0 · Reply
Latest News on OVID
Ovid Therapeutics Inc. - Special Call

Oct 3, 2025, 12:52 PM EDT - 22 days ago

Ovid Therapeutics Inc. - Special Call


swingtraderqueen
swingtraderqueen Oct. 23 at 2:15 PM
$OVID all in on this $YYAI $ZOMDF $BYND
0 · Reply
swingtraderqueen
swingtraderqueen Oct. 23 at 2:14 PM
0 · Reply
venkbaskar
venkbaskar Oct. 21 at 7:26 PM
$OVID $5 in January
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 21 at 3:25 PM
$OVID Added some
0 · Reply
lucabrix
lucabrix Oct. 20 at 7:35 PM
$OVID great times in front of us!
0 · Reply
Tonydarien
Tonydarien Oct. 20 at 2:56 PM
$OVID same old crap, a different smell. Day traders playing this in a $0.35 channel. We need positive top line for OV350 to launch this to $3.00.
0 · Reply
therealcryptocowboy
therealcryptocowboy Oct. 19 at 12:22 AM
$OVID need help fam please sign and share! https://c.org/XbNrDf8F6r
0 · Reply
stocksmanagement
stocksmanagement Oct. 18 at 6:22 AM
$OVID Check out this article from TipRanks | Ovid Therapeutics price target raised to $5 from $3 at B. Riley | https://tipranks.onelink.me/WJho/9vnu72lg
0 · Reply
docBNM
docBNM Oct. 17 at 5:01 PM
$OVID seems like the supposed good news is not impressing Mr. Mkt. How low will this POS go ??!?!?!
0 · Reply
Troopers
Troopers Oct. 17 at 1:12 PM
$OVID OV329 was studied in models of neuropathic pain and inflammatory pain, and it showed great activity against pain in both models. Importantly, it didn’t show tolerance or addiction. The study was published in PNAS (link below). These would be blockbuster indications! “Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction” https://www.pnas.org/doi/10.1073/pnas.2318833121
0 · Reply
Jtlo
Jtlo Oct. 15 at 5:07 PM
$XLO this one might go crazy. $OVID $MLTX $IOBT
0 · Reply
Eagley3k
Eagley3k Oct. 14 at 8:28 PM
$OVID looks ready to continue upward
0 · Reply
lucabrix
lucabrix Oct. 14 at 7:14 PM
$OVID Back on track!
0 · Reply
CasperPuff
CasperPuff Oct. 14 at 7:13 PM
$OVID nice. Going to $3. Then $5
0 · Reply
TJknows
TJknows Oct. 14 at 3:56 AM
$OVID This guy gets it.
1 · Reply
stocksmanagement
stocksmanagement Oct. 13 at 4:55 PM
$OVID https://uk.finance.yahoo.com/news/ovid-stock-soars-39-month-142700390.html
0 · Reply
Jtlo
Jtlo Oct. 12 at 3:05 PM
$OVID which one should I place some money in $GANX $COYA $ATHA
4 · Reply
jarias115
jarias115 Oct. 12 at 1:06 AM
$OVID let it bleed so I can get in under 1.20
1 · Reply
stocksmanagement
stocksmanagement Oct. 10 at 8:21 PM
$OVID Check out this article from TipRanks | Ovid Therapeutics price target raised to $5 from $3 at B. Riley | https://tipranks.onelink.me/WJho/1a2ind8a🔥🔥🔥
0 · Reply
ZacksResearch
ZacksResearch Oct. 10 at 5:50 PM
$OVID surges 39.2% on promising Phase I epilepsy study results! 🚀 OV329, Ovid's lead candidate, shows strong GABAergic activity, boosting inhibition by up to 53% on the APB muscle. This breakthrough could position OV329 as a best-in-class seizure treatment. See what makes this a compelling buy with Zacks Rank #2 👉 https://www.zacks.com/stock/news/2766357/ovid-stock-soars-39-in-a-month-following-upbeat-epilepsy-study-data?cid=sm-stocktwits-2-2766357-body-15657&ADID=SYND_STOCKTWITS_TWEET_2_2766357_BODY_15657
0 · Reply
ZacksResearch
ZacksResearch Oct. 10 at 4:50 PM
$OVID rockets 39% in a month 🚀 Phase I epilepsy study data showed superior efficacy for its lead candidate, OV329 — early signs pointing toward best-in-class potential. See what could drive OVID’s next move 👉 https://www.zacks.com/stock/news/2766357/ovid-stock-soars-39-in-a-month-following-upbeat-epilepsy-study-data?cid=sm-stocktwits-2-2766357-teaser-15644&ADID=SYND_STOCKTWITS_TWEET_2_2766357_TEASER_15644
0 · Reply
Thorilium
Thorilium Oct. 10 at 3:59 PM
$OVID $ABVE so the one thing this poster is bullish about is going red :-)))
0 · Reply